Abstract
Thirty-two patients with acute lymphoblastic leukemia (ALL) were given cyclophosphamide, 120 mg/kg, and total body irradiation (TBI), 10-12 Gy, followed by an allergic bone marrow transplant (BMT). Seven patients were in their first remission: 4 survived 8-24 months post-BMT and 3 died of BMT-related complications. Twenty-five patients were in their second remission: 12 survived, 7-50 months post-BMT. The actuarial survival for patients in 1st and 2nd CR is 57% and 40 %, respectively (p = 0.1). The overall survival for patients less than or older than 15 years of age is 73% and 50%, respectively (p = 0.2). The actuarial risk of relapse is currently 0% and 50% for 1st and 2nd CR patients (p = 0.06). Factors influencing relapse in 2nd CR patients are the length of first remission (p = 0.01), the severity of acute GvHD (p = 0.02), and the severity of chronic GvHD (p = 0.03). This study points out an age-dependent tolerance of transplant procedures in ALL, and a high relapse rate in 2nd remission patients, possibly influenced by the duration of first remission and the severity of GvHD.
| Original language | English |
|---|---|
| Pages (from-to) | 135-138 |
| Number of pages | 4 |
| Journal | Haematologica |
| Volume | 71 |
| Issue number | 2 |
| Publication status | Published - 1986 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission. / van Lint, M. T.; Bacigalupo, A.; Frassoni, F.; Repetto, M.; Piaggio, G.; Congiu, M.; Vitale, V.; Scarpati, D.; Franzone, P.; Corvò, R.
In: Haematologica, Vol. 71, No. 2, 1986, p. 135-138.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission
AU - van Lint, M. T.
AU - Bacigalupo, A.
AU - Frassoni, F.
AU - Repetto, M.
AU - Piaggio, G.
AU - Congiu, M.
AU - Vitale, V.
AU - Scarpati, D.
AU - Franzone, P.
AU - Corvò, R.
PY - 1986
Y1 - 1986
N2 - Thirty-two patients with acute lymphoblastic leukemia (ALL) were given cyclophosphamide, 120 mg/kg, and total body irradiation (TBI), 10-12 Gy, followed by an allergic bone marrow transplant (BMT). Seven patients were in their first remission: 4 survived 8-24 months post-BMT and 3 died of BMT-related complications. Twenty-five patients were in their second remission: 12 survived, 7-50 months post-BMT. The actuarial survival for patients in 1st and 2nd CR is 57% and 40 %, respectively (p = 0.1). The overall survival for patients less than or older than 15 years of age is 73% and 50%, respectively (p = 0.2). The actuarial risk of relapse is currently 0% and 50% for 1st and 2nd CR patients (p = 0.06). Factors influencing relapse in 2nd CR patients are the length of first remission (p = 0.01), the severity of acute GvHD (p = 0.02), and the severity of chronic GvHD (p = 0.03). This study points out an age-dependent tolerance of transplant procedures in ALL, and a high relapse rate in 2nd remission patients, possibly influenced by the duration of first remission and the severity of GvHD.
AB - Thirty-two patients with acute lymphoblastic leukemia (ALL) were given cyclophosphamide, 120 mg/kg, and total body irradiation (TBI), 10-12 Gy, followed by an allergic bone marrow transplant (BMT). Seven patients were in their first remission: 4 survived 8-24 months post-BMT and 3 died of BMT-related complications. Twenty-five patients were in their second remission: 12 survived, 7-50 months post-BMT. The actuarial survival for patients in 1st and 2nd CR is 57% and 40 %, respectively (p = 0.1). The overall survival for patients less than or older than 15 years of age is 73% and 50%, respectively (p = 0.2). The actuarial risk of relapse is currently 0% and 50% for 1st and 2nd CR patients (p = 0.06). Factors influencing relapse in 2nd CR patients are the length of first remission (p = 0.01), the severity of acute GvHD (p = 0.02), and the severity of chronic GvHD (p = 0.03). This study points out an age-dependent tolerance of transplant procedures in ALL, and a high relapse rate in 2nd remission patients, possibly influenced by the duration of first remission and the severity of GvHD.
UR - http://www.scopus.com/inward/record.url?scp=0022980428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022980428&partnerID=8YFLogxK
M3 - Article
C2 - 3087834
AN - SCOPUS:0022980428
VL - 71
SP - 135
EP - 138
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 2
ER -